Sunday, November 10 |
|
| 7:00 am - 6:00 pm | Registration Open |
| 8:00 am - 8:10 am |
Announcements |
| 8:10 am - 9:05 am | Keynote Address A Genomic Approach to the Discovery of Therapeutic Proteins and Antibody Drugs William Haseltine, PhD Human Genome Sciences, Inc. |
| 9:05 am - 11:30 am |
Pharmacogenomics/Discovery Robert Zimmerman, SD |
| 9:05 am - 9:30 am | Pharmacogenomic Applied to Drug Development Joseph Rininger, PhD CuraGen Corporation |
| 9:30 am - 9:55 am | Directed Molecular Evolution of Vaccines
and Immunotherapeutics Juha Punonnen, MD, PhD Maxygen, Inc. |
| 9:55 am - 10:15 am | Break |
| 10:15 am - 10:40 am | Approaches for Identifying and Accelerating
the Prioritization of All the Potential Targets and Therapeutic
Proteins in the Genome Benjamin G. Cocks, PhD Incyte Genomics, Inc. |
| 10:40 am - 11:05 am | Classification and Diagnostic Prediction
of Cancers using Gene Expression Profiling and Artificial Neural Networks Javed Khan, MD Center for Cancer Research National Cancer Institute |
| 11:05 am - 11:30 am | Clinical Proteomics: Toward Personalized
Molecular Medicine Lance Liotta, MD, PhD Center for Cancer Research National Cancer Institute |
| 11:30 am - 1:00 pm | SBT Member Lunch/Business Meeting (SBT Members Only) |
| 11:30 am - 1:00 pm | Box Lunch/Posters Session (authors must be present) |
| 1:00 pm - 2:30 pm | Presidential Session Chair: Robert O. Dillman, MD SBT President Hoag Cancer Center |
| 1:00 pm - 1:15 pm | Ranitidine as Adjuvant Treatment in
Colorectal Cancer: Influence of Blood Transfusion and
Postoperative Bacterial Infections Hans Jorgen Nielsen, MD Hvidovre University Hospital |
| 1:15 pm - 1:30 pm | Phase I/IB trial of the
Immunocytokine hu14.18-IL2 in Patients with GD2-Positive Tumors David King, MD University of Wisconsin, Comprehensive Cancer Center |
| 1:30 pm - 1:45 pm | Prophylactic Antitumor Efficacy of a
Combination Therapy With a Xenogeneic Cell Line Producing
Flt3-Ligand (FL), Tumor Cell Lysate, and Interleukin-2
in Mice With Syngeneic Colon Cancer Eugene Kim, MD State University of New York at Brooklyn School of Medicine |
| 1:45 pm - 2:00 pm | Inhibition of Tumor Progression and
Neoangiogenesis Using Cyclic RGD- Peptides in a Chemically
Induced Colon Carcinoma in Rats Joerg Haier, MD, PhD University Hospital Muenster, Molecular Biology Lab |
| 2:00 pm - 2:15 pm | Intratumoral Expansion of Tumor-Specific
B Cells in Invasive Ductal Carcinoma of the Breast Julia A. Coronella, PhD University of Arizona, Arizona Cancer Center |
| 2:15 pm - 2:30 pm | Signaling Defects in CD8+CD27- CD45RO-
Circulating Effector Cells in Patients with Cancer Iris Kuss, MD University of Pittsburgh Cancer Institute |
| 2:30 pm - 2:50 pm | Break |
|
Concurrent Session 1
|
Concurrent Session 2
|
||
| 2:50 pm - 4:55 pm | Antibody Therapy Co-Chairs: Thomas Davis, MD Medarex, Inc. Stephen Gillies, PhD |
2:50 pm - 4:50 pm | Gene Therapy Co-Chairs: Stanton Gerson, MD Case Western Reserve University
|
| 2:50 pm - 3:10 pm | CD 22-Directed Immunotherapy of Lymphoma
John Leonard, MD Cornell University |
2:50 pm - 3:15 pm | Transplantation of Stem Cells: Homing
and Selection with Drug Resistance Genes Stanton Gerson, MD Case Western Reserve University |
| 3:10 pm - 3:30 pm | Humanized Anti–HLA-DR Monoclonal
Antibody Hu1D10 (Remitogen) for the Treatment of Relapsed
Non-Hodgkin’s Lymphoma: A Phase I Trial Brian K. Link, MD University of Iowa, Holden Comprehensive Cancer Center |
3:15 pm - 3:40 pm | Clinical Results of a PSA-Selective,
Replication-Competent Adenovirus for the Treatment of
Prostate Cancer Theodore DeWeese, MD Johns Hopkins Oncology Center |
| 3:30 pm - 3:50 pm | Anti-Cytotoxic T-Lymphocyte-Associated
Antigen-4 (anti-CTLA-4) Monoclonal Antibody (MDX-CTLA-4)
in Patients with Metastatic Melanoma Stephen Hodi, MD Dana-Farber Cancer Institute |
3:40 pm - 4:05 pm | Speaker TBD |
| 3:50 pm - 4:10 pm | Early-Phase Clinical Development of the
Immunocytokine EMD 273066 (huKS-IL2): Laboratory and Safety
Findings in Patients with Prostate Cancer Lothar Finke, MD EMD Pharmaceuticals |
4:05 pm - 4:30 pm | Differential Impact of Local Production
Interleukin-2 and Interleukin-12 on Initial Appearance
and Long-term Progression of B16F10 Melanoma in Mice Morihiro Watanabe, MD, PhD Center for Cancer Research National Cancer Institute |
| 4:10 pm - 4:25 pm | Synergistic Anti-tumor Responses Against
Metastatic Cancer Using Antibodies to CD40 and IL2: Coordination
of Dendritic Cell and T Cell Arms of the Immune Response
William J. Murphy, PhD Center for Cancer Research National Cancer Institute |
4:30 pm - 4:45 pm | A DNA Vaccine Encoding Genetic Fusions
of CEA and GMCSF Jose Lima, MD University of Alabama at Birmingham, Wallace Tumor Institute |
| 4:25 pm - 4:40 pm | Recurrent Murine Neuroblastomas Increase
or Decrease MHC Class I Expression to Respectively Escape
NK- or T Cell-Dependent Immunotherapy Zane C. Neal, PhD University of Wisconsin |
4:45 pm - 5:00 pm | Systemic p53 Gene Therapy of Cancer with
Immunolipoplexes Targeted by Anti- Transferrin Receptor
scFv Liang Xu MD, PhD Lombardi Cancer Center Georgetown University |
| 4:40 pm – 4:55 pm | Combined Administration of Antibodies
to Human Interleukin-8 and Epidermal Growth Factor Receptor
Results in Increased Anti-metastatic Effects on Human
Breast Carcinoma Xenografts Rosalba Salcedo, PhD Center for Cancer Research National Cancer Institute |
5:00 pm - 6:30 pm | Presidential Reception/Presidential Award
Announcement Chair: Robert O. Dillman, MD SBT President Hoag Cancer Center |
